HER-dimerization inhibitors: evaluating pertuzumab in women's cancers

Bibliography

• What you need to know about breast cancer. Bethesda, Maryland: National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/types/breast [Last Accessed November 2009]
   Google Scholar
• Ovarian Cancer. Bethesda, Maryland: National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/types/ovarian [Last accessed 10 November 2009]
   Google Scholar
• Baselga J, Tripathy D, Medelsohn J, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14(3):737-44
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study on the efficacy and safetu of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancerthat has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Seidman AD, Fornier MN, Esteva FJ, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-95
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-postitive breast cancer [abstract 512]. J Clin Oncol 2007;25(Suppl)
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehthinn PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;284:122-30
   Google Scholar
• Robert NJ, Eiermann W, Pienkowski T, BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up [abstract 19647]. J Clin Oncol 2007;25 (Suppl)
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarianor primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncolgy Group. J Clin Oncol 2003;21(2):283-90
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster MD, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
   PubMed Web of Science ®Google Scholar
• Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 2002;26:109-64
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the Erb B signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Natha R, Yuan LXH, Zhang B, Insulin-like growth factor-I Receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65(23):11118-28
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramayar KX, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:757-60
   Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Insights into ErbB signaling from the structure of the ErbB-2 pertuzumab complex. Cancer Cell 2004;5(4):317-28
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37
   PubMed Web of Science ®Google Scholar
• Lewis GD, Lofgren JA, McMurtrey AE, Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996;56:1457-65
   PubMed Web of Science ®Google Scholar
• Mann M, Sheng H, Shao J, Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-925
   PubMed Web of Science ®Google Scholar
• Natha R, Hung MC, Esteva F. The HER-2-targeting antibodies trastuzumaband pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-46
   PubMed Web of Science ®Google Scholar
• Yao E, Zhou W, Lee-Hoenflich ST, Suppression of HER2/HER3-mediatedgrowth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor,trastuzumab and pertuzumab. Clin Cancer Res 2009;15(12):4147-55
   PubMed Web of Science ®Google Scholar
• Friess T, Bauer S, Burger AM, In vivo activity of recombinanat humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract 496]. Eur J Cancer 2002;38 (Suppl 7):S149
   Google Scholar
• Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11(14):5300-9
   PubMed Web of Science ®Google Scholar
• Pohl M, Stricker I, Schoeneck A, Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 2009;135(10):1377-86
   PubMed Web of Science ®Google Scholar
• Arpino G, Gutierrez C, Weiss H, Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99(9)694-705
   PubMed Web of Science ®Google Scholar
• Adams CW, Allison DE, Flagella K, Humanization of a recombinant monoclonal antibody to producea therapeutic HER dimerizationinhibitor, pertuzumab. Cancer Immunol Immunother 2006;55(6):717-27
   PubMed Web of Science ®Google Scholar
• Agus, DB, Gordon MS, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23(11):2534-43
   PubMed Web of Science ®Google Scholar
• Cortes J, Basega J, Kellokumpu-Lehtinen P, Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastático breast cancer (MBC) with low expression of HER2 [abstract 3068]. J Clin Oncol 2005;23 (Suppl)
   Google Scholar
• Gelmon KA, Fumeoleau P, Verma S, Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy [abstract 1026]. J Clin Oncol 2008;26 (Suppl)
   Google Scholar
• Cortes J, Baselga J, Petrella T, Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer [abstract 155]. J Clin Oncol 2009;27 (Suppl)
   Google Scholar
• Genentech, Inc. A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated her2-positive metastatic breast cancer CLEOPATRA. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00567190?term=pertuzumab&rank=14 [Last accessed 30 November 2009]
   Google Scholar
• Hoffmann-La Roche. A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00545688?term=pertuzumab&rank=10 [Last accessed 30 November 2009]
   Google Scholar
• Hoffmann-La Roche. A Study of pertuzumab in combination with herceptin and chemotherapy in patients with HER2-positive breast cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00976989?term=pertuzumab&rank=6 [Last accessed 30 November 2009]
   Google Scholar
• Gordon MS, Matei D, Aghajanian C, Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24(26):4324-32
   PubMed Web of Science ®Google Scholar
• Amler L, Makhija S, Januario T, HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant ovarian cancer [abstract 5552]. J Clin Oncol 2008;26 (Suppl)
   Google Scholar
• Dizon DS, Makhija S. HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opin Drug Discov 2008;3(11):1-7
   PubMedGoogle Scholar
• Kaye SB, Poole CJ, Bidzinksi M, A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer [abstract 5520]. J Clin Oncol 2008;26 (Suppl)
   Google Scholar
• Nagumo Y, Faratian D, Mullen P, Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implication for peruzumab sensitivity. Mol Cancer Res 2009;7(9):1563-71
   PubMed Web of Science ®Google Scholar
• Natha R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8(6):215
   PubMedGoogle Scholar